sur Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Updates on U.S. Patent Filings for Drug Delivery Platform
Aspire Biopharma Holdings, Inc., listed on NASDAQ as ASBP, has announced an update on its patent applications for a sublingual drug delivery platform. The company originally filed provisional patents with the U.S. Patent and Trademark Office in March 2023 and October 2024. These patents cover formulations for rapidly absorbing aspirin via the oral mucosa, bypassing the gastrointestinal tract.
The patent filings are a strategic move to enhance Aspire's intellectual property portfolio. Aspire's CEO, Kraig Higginson, highlighted the potential of this technology to revolutionize sublingual drug delivery and improve treatment outcomes. Key benefits include fast absorption, vital for handling cardiac emergencies and pain management.
Aspire plans to initiate a bioavailability study in April 2025, with further clinical trials anticipated throughout the year. The company aims to bolster its path to commercialization with these developments.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Aspire Biopharma, Inc.